Role of monocyte-to-lymphocyte ratio in predicting sorafenib response in patients with advanced hepatocellular carcinoma

PURPOSE: Sorafenib is the first-line treatment for patients with unresectable hepatocellular carcinoma (HCC), and its clinical response rate is only about 10%. In clinical practice, some HCC patients obtain favorable overall survival (OS) to the treatment of sorafenib while some patients do not demo...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Onco Targets Ther
Hlavní autoři: Zhu, Zhenfeng, Xu, Litao, Zhuang, Liping, Ning, Zhouyu, Zhang, Chenyue, Yan, Xia, Lin, Junhua, Shen, Yehua, Wang, Peng, Meng, Zhiqiang
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2018
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6188073/
https://ncbi.nlm.nih.gov/pubmed/30349306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S173275
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky